Generic Name and Formulations:
Dantrolene sodium 20mg; per vial; lyophilized pwd for IV inj after reconstitution; contains mannitol.
US WorldMeds, LLC
Indications for REVONTO:
Management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia (MH). Prevention of malignant hyperthermia in susceptible patients during pre-op or sometimes post-op.
Adults and Children:
Treatment: Give by rapid IV push at a minimum of 1mg/kg, continue until symptoms subside or max cumulative dose of 10mg/kg has been reached; if physiologic and metabolic abnormalities reappear, repeat regimen. Prevention: Start approx. 75 mins prior to anesthesia, give 2.5mg/kg by IV infusion over 1hr; may give additional doses during anesthesia or prolonged surgery.
Institute supportive measures (eg, discontinue MH-triggering agents, increase oxygen requirements, manage metabolic acidosis, cooling if necessary, monitor urinary output and electrolyte imbalance). Monitor for skeletal muscle weakness, difficulty swallowing and choking. Increased risk of hepatic injury (esp. in females or patients >35yrs of age); monitor hepatic function frequently (eg, SGOT, SGPT). Avoid extravasation. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Muscle relaxant (skeletal).
Avoid MH-triggering agents. Concomitant calcium channel blockers (eg, verapamil): not recommended. Caution with concomitant tranquilizers. May potentiate vecuronium-induced neuromuscular block. Protein binding reduced by warfarin or clofibrate; and increased by tolbutamide.
Loss of grip strength, weakness in the legs, drowsiness, dizziness, thrombophlebitis, tissue necrosis secondary to extravasation, inj site reactions (eg, pain, erythema, swelling); rare: pulmonary edema, urticaria, erythema.
Clinical Pain Advisor Articles
- Chronic Neuropathic Pain Updated Classification by IASP for ICD-11
- Buprenorphine-Naloxone Found to Be More Cost-Effective Than Extended-Release Naltrexone
- Ultrasound-Guided C2 Coblation May Be Effective for Cervicogenic Headache
- Meta-Analysis of Opioid Treatment for Chronic Noncancer Pain
- Opioids Found to Increase Risk for Community-Acquired Pneumonia, Particularly in HIV
- Reviewing the Use of Buprenorphine in Perioperative Pain Management
- Early Physical Therapy for Musculoskeletal Pain May Reduce Opioid Use
- External Trigeminal Nerve Stimulation May Alleviate Migraine Pain
- IASP Updates Diagnosis Criteria for Chronic Primary Pain for ICD-11
- Galcanezumab Provides Persistent Preventive Effects in Episodic, Chronic Migraine
- Comparable Analgesia With Low-Dose IV Ketamine, Morphine for Acute Pain
- Benzodiazepines, if Prescribed, May Not Affect Methadone Treatment Retention
- When Opioid Prescribing Guidelines Become Rules
- IV Fluid Confers No Significant Treatment Effect on Migraine Pain
- American Headache Society Releases Position Statement on Novel Preventive and Acute Migraine Treatments